Your browser doesn't support javascript.
loading
Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study.
de Vos, Thijs W; Winkelhorst, Dian; Árnadóttir, Valgerdur; van der Bom, Johanna G; Canals Surís, Carme; Caram-Deelder, Camila; Deschmann, Emöke; Haysom, Helen E; Hverven, Hem Birgit C; Lozar Krivec, Jana; McQuilten, Zoe K; Muñiz-Diaz, Eduardo; Nogués, Núria; Oepkes, Dick; Porcelijn, Leendert; van der Schoot, C Ellen; Saxonhouse, Matthew; Sola-Visner, Martha; Tiblad, Eleonor; Tiller, Heidi; Wood, Erica M; Young, Vanessa; Zeleznik, Mojca; de Haas, Masja; Lopriore, Enrico.
Affiliation
  • de Vos TW; Willem-Alexander Children's Hospital, Department of Pediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, Netherlands; Center of Clinical Transfusion Research, Sanquin Research, Leiden, Netherlands; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, Ne
  • Winkelhorst D; Department of Obstetrics and Gynecology, Leiden University Medical Center, Leiden, Netherlands; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, Netherlands.
  • Árnadóttir V; Department of Pediatrics, Division of Neonatology, Karolinska University Hospital, Stockholm, Sweden.
  • van der Bom JG; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands.
  • Canals Surís C; Immunohematology Laboratory, Blood and Tissue Bank, Barcelona, Spain.
  • Caram-Deelder C; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands; Center of Clinical Transfusion Research, Sanquin Research, Leiden, Netherlands.
  • Deschmann E; Department of Pediatrics, Division of Neonatology, Karolinska University Hospital, Stockholm, Sweden.
  • Haysom HE; Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Hverven HBC; Department of Obstetrics and Gynecology, University Hospital of North Norway, Tromsø, Norway.
  • Lozar Krivec J; Department of Neonatology, Division of Paediatrics, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • McQuilten ZK; Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Department of Clinical Haematology, Monash Health, Melbourne, VIC, Australia.
  • Muñiz-Diaz E; Immunohematology Laboratory, Blood and Tissue Bank, Barcelona, Spain.
  • Nogués N; Immunohematology Laboratory, Blood and Tissue Bank, Barcelona, Spain.
  • Oepkes D; Department of Obstetrics and Gynecology, Leiden University Medical Center, Leiden, Netherlands.
  • Porcelijn L; Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, Netherlands.
  • van der Schoot CE; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, Netherlands.
  • Saxonhouse M; Division of Neonatology, Levine Children's Hospital, Atrium Healthcare, Wake Forest School of Medicine, Charlotte, NC, USA.
  • Sola-Visner M; Division of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Tiblad E; Center for Fetal Medicine, Pregnancy Care and Delivery, Women's Health, Karolinska University Hospital, Stockholm, Sweden; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Tiller H; Department of Obstetrics and Gynecology, University Hospital of North Norway, Tromsø, Norway; Women's Health and Perinatology Research Group, Department of Clinical Medicine, Faculty of Health Sciences, Arctic University of Norway, Tromsø, Norway.
  • Wood EM; Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Department of Clinical Haematology, Monash Health, Melbourne, VIC, Australia.
  • Young V; Division of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Zeleznik M; Department of Neonatology, Division of Paediatrics, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • de Haas M; Department of Hematology, Leiden University Medical Center, Leiden, Netherlands; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, Netherlands; Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, Netherlands.
  • Lopriore E; Willem-Alexander Children's Hospital, Department of Pediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, Netherlands.
Lancet Haematol ; 9(11): e844-e853, 2022 Nov.
Article in En | MEDLINE | ID: mdl-36108655
ABSTRACT

BACKGROUND:

Children affected by fetal and neonatal alloimmune thrombocytopenia (FNAIT) are at risk of severe intracranial haemorrhage. Management in the postnatal period is based on sparse evidence. We aimed to describe the contemporary management and outcomes of patients with FNAIT in high-income countries.

METHODS:

In this multicentre, retrospective, cohort study, we set up a web-based registry for the collection of deidentified data on the management and course of neonates with FNAIT. Eight centres from seven countries (Australia, Norway, Slovenia, Spain, Sweden, the Netherlands, and the USA) participated. Eligibility criteria comprised neonates with FNAIT being liveborn between Jan 1, 2010, and Jan 1, 2020; anti-human platelet antigen (HPA) alloantibodies in maternal serum; confirmed maternal and fetal HPA incompatibility; and bleeding detected at antenatal ultrasound, neonatal thrombocytopenia (<150 × 109 platelets per L), or both in the current or previous pregnancy. Clinical data were retrieved from local medical records of the first neonatal admission and entered in the registry. The key outcome was the type of postnatal treatment given to neonates with FNAIT. Other outcomes were daily median platelet counts in the first week of life, median platelet count increment after first unmatched versus first matched transfusions, and the proportion of neonates with mild or severe bleeding.

FINDINGS:

408 liveborn neonates with FNAIT were entered into the FNAIT registry, of whom 389 from Australia (n=74), Norway (n=56), Slovenia (n=19), Spain (n=55), Sweden (n=31), the Netherlands (n=138), and the USA (n=16) were included in our analyses. The median follow-up was 5 days (IQR 2-9). More neonates were male (241 [64%] of 379) than female (138 [36%]). Severe thrombocytopenia (platelet count <50 × 109 platelets per L) was reported in 283 (74%) of 380 neonates, and extreme thrombocytopenia (<10 × 109 platelets per L) was reported in 92 (24%) neonates. Postnatal platelet count nadir was higher in the no-treatment group than in all other groups. 163 (42%) of 389 neonates with FNAIT received no postnatal treatment. 207 (53%) neonates received platelet transfusions, which were either HPA-unmatched (88 [43%] of 207), HPA-matched (84 [41%]), or a combination of both (35 [17%]). The proportion of neonates who received HPA-matched platelet transfusions varied between countries, ranging from 0% (Slovenia) to 63% (35 of 56 neonates; Norway). Postnatal intravenous immunoglobulin treatment was given to 110 (28%) of 389 neonates (alone [n=19] or in combination with platelet transfusions [n=91]), with the proportion receiving it ranging from 12% (17 of 138 neonates; the Netherlands) to 63% (ten of 16 neonates; the USA) across countries. The median platelet increment was 59 × 109 platelets per L (IQR 35-94) after HPA-unmatched platelet transfusions and 98 × 109 platelets per L (67-134) after HPA-matched platelet transfusions (p<0·0001). Severe bleeding was diagnosed in 23 (6%) of 389 liveborn neonates, with one having a severe pulmonary haemorrhage and 22 having severe intracranial haemorrhages. Mild bleeding was diagnosed in 186 (48%) neonates.

INTERPRETATION:

Postnatal management of FNAIT varies greatly between international centres, highlighting the absence of consensus on optimal treatments. Our data suggest that HPA-matched transfusions lead to a larger median platelet count increment than HPA-unmatched transfusions, but whether HPA matching is also associated with a reduced risk of bleeding remains unknown.

FUNDING:

Sanquin.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Antigens, Human Platelet / Thrombocytopenia, Neonatal Alloimmune Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Child / Female / Humans / Male / Newborn / Pregnancy Language: En Journal: Lancet Haematol Year: 2022 Type: Article Affiliation country: Niger

Full text: 1 Database: MEDLINE Main subject: Antigens, Human Platelet / Thrombocytopenia, Neonatal Alloimmune Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Child / Female / Humans / Male / Newborn / Pregnancy Language: En Journal: Lancet Haematol Year: 2022 Type: Article Affiliation country: Niger